GRANTS

154 RESULTS

To submit a grant posting, please fill out our web form or download the form so that you can email us at grants@alzforum.org. List the sponsor name, amount, due date, and contact information. This is a free service.

Please Note: We remove grant postings after 6 months. If you would like your listing to be posted longer or taken down sooner, please contact us at grants@alzforum.org.

Research Career Enhancement Award to Advance Therapy Development for Alzheimer's (K18)

Sponsor: National Institute on Aging

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Comparative Biology of Neurodegeneration (R21)

Sponsor: National Institute on Aging

Award: NIA intends to commit $2.2M in FY17 to fund up to 10 awards.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01)

Sponsor: National Institute on Aging

Award: NIA intends to commit $3 million in FY 2017 to fund two to four awards.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01)

Sponsor: National Institute on Aging

Award: NIA intends to commit $7.5 million in FY 2017 to fund five to 10 awards.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimers Disease (R01)

Sponsor: National Institute on Aging

Award: NIA intends to commit up to $3 million (total costs) in FY 2017 to support up to seven awards. The number of awards is contingent upon NIH appropriations.

Due Date: February 10, 2017, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Multimorbidity in Alzheimers Disease Impacts Choice of Ancillary Treatments (R21/R33)

Sponsor: National Institute on Aging

Award: NIA intends to commit $3.2 million in FY 2017 to fund four to six awards. The number of awards is contingent upon NIH appropriations.

Due Date: January 12, 2017, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Multimorbidity in Alzheimers Disease Impacts Choice of Ancillary Treatments (R33)

Sponsor: National Institute on Aging

Award: NIA intends to commit $3.2 million in FY 2017 to fund four to six awards. The number of awards is contingent upon NIH appropriations.

Due Date: January 12, 2017, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Role of Age-Associated Metabolic Changes in Alzheimer's Disease (AD) (R01)

Sponsor: National Institute on Aging

Award: NIA intends to commit $2.7 million in FY 2017 to fund six to eight awards.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimers Disease (R01)

Sponsor: National Institute on Aging

Award: NIA intends to commit up to $3 million (total costs) in FY 2017 to support up to seven awards. The number of awards is contingent upon NIH appropriations.

Due Date: February 10, 2017, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Clinical Trials for Frontotemporal Degeneration RFP

Sponsor: Alzheimer's Drug Discovery Foundation through a partnership with the Association for Frontotemporal Degeneration

Award: $500,000-$2 million

Due Date: Letter of Intent: November 15, 2016. Invited Full Proposal: February 15, 2017.

Animal and Biological Material Resource Centers (P40)

Sponsor: National Institutes of Health, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization.

Emerging Global Leader Award (K43)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: December 14, 2016; December 14, 2017; and December 13, 2018, by 5 p.m. local time of applicant organization.

Current Filters

No filters selected

Filter By